Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

21 May 2014 11:52

RNS Number : 6959H
GoldmanSachs International
21 May 2014
 



 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN SACHS INTERNATIONAL

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date dealing undertaken:

20 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES - disclosed previously for PFIZER INC

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

USD 0.25 ordinary

Purchases

1,872,0075,88215,000

43.0850 GBP478.3000 SEK72.2700 USD

41.8850 GBP468.0000 SEK72.2700 USD

USD 0.25 ordinary

Sales

1,431,1785,882

43.0850 GBP474.4000 SEK

41.9150 GBP469.0000 SEK

ADR

Purchases

50,000

72.4131 USD

72.3189 USD

ADR

Sales

50,000

72.3660 USD

72.3660 USD

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

Opening a short position

1,000

42.0450 GBP

USD 0.25 ordinary

CFD

Opening a long position

15,000

42.1389 GBP

USD 0.25 ordinary

CFD

Opening a short position

380

42.1500 GBP

USD 0.25 ordinary

CFD

Opening a short position

37,860

42.1576 GBP

USD 0.25 ordinary

CFD

Opening a short position

5,546

42.2479 GBP

USD 0.25 ordinary

CFD

Opening a short position

146,078

42.2479 GBP

USD 0.25 ordinary

CFD

Opening a long position

6,500

42.2695 GBP

USD 0.25 ordinary

CFD

Opening a long position

18,400

42.3325 GBP

USD 0.25 ordinary

CFD

Reducing a short position

7,180

42.6685 GBP

USD 0.25 ordinary

CFD

Opening a short position

125

42.6802 GBP

USD 0.25 ordinary

CFD

Reducing a short position

500

42.7204 GBP

USD 0.25 ordinary

CFD

Reducing a short position

12,500

42.8083 GBP

USD 0.25 ordinary

CFD

Opening a short position

12,500

42.8349 GBP

USD 0.25 ordinary

CFD

Opening a short position

7,180

42.8445 GBP

USD 0.25 ordinary

CFD

Reducing a short position

2,000

42.8550 GBP

USD 0.25 ordinary

CFD

Reducing a short position

14,394

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a short position

6,780

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a short position

3,826

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a long position

3,984

42.9066 GBP

USD 0.25 ordinary

CFD

Opening a short position

50,000

43.0461 GBP

USD 0.25 ordinary

CFD

Opening a long position

10,000

43.0850 GBP

USD 0.25 ordinary

CFD

Reducing a short position

380

43.0850 GBP

USD 0.25 ordinary

CFD

Opening a short position

15,000

72.2700 USD

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

ADR

Call Option / (1.00 : 100.00)

Purchasing

750 (75,000)

77.5000 USD

AMERICAN

19/07/2014

2.4200 USD

ADR

Call Option / (1.00 : 100.00)

Selling

750 (75,000)

72.5000 USD

AMERICAN

19/07/2014

4.1200 USD

ADR

Put Option / (1.00 : 100.00)

Purchasing

39 (3,900)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Purchasing

11 (1,100)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Selling

11 (1,100)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Selling

39 (3,900)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

21 May 2014

Contact name:

Aadithya Rao and Yiannis Bardis

Telephone number:

+44(20) 7051 9046 / +44(20) 7774 7107

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDUBUDBGSB
Date   Source Headline
21st Feb 202311:00 amRNSAnnual Financial Report
13th Feb 20232:01 pmRNSDirector/PDMR Shareholding
13th Feb 20232:00 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSFinal Results
1st Feb 20233:00 pmRNSTotal Voting Rights
26th Jan 20236:15 pmRNSUpdate on Evusheld US EUA
16th Jan 20237:00 amRNSAcquisition of Neogene Therapeutics completed
11th Jan 20231:00 pmRNSAirsupra (PT027) approved in US for asthma
9th Jan 20237:00 amRNSAstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 20233:00 pmRNSTotal Voting Rights
30th Dec 202211:00 amRNSDirector/PDMR Shareholding
28th Dec 20227:05 amRNSCalquence Japan approval for treatment-naïve CLL
28th Dec 20227:00 amRNSImfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 20227:05 amRNSLynparza approved in EU for prostate cancer
21st Dec 20227:00 amRNSImfinzi approved in EU for biliary tract cancer
19th Dec 20227:20 amRNSEnhertu recommended for EU approval in HER2-low BC
19th Dec 20227:15 amRNSEnhertu approved in EU for gastric cancer
19th Dec 20227:10 amRNSImfinzi + Imjudo recommended for approvals in EU
19th Dec 20227:05 amRNSUpdate on Imfinzi PEARL trial
19th Dec 20227:00 amRNSForxiga CHMP opinion for symptomatic chronic HF
15th Dec 20227:00 amRNSUpdate on US review of Lynparza PROpel sNDA
8th Dec 20221:30 pmRNSCapivasertib PFS in HR-positive breast cancer
1st Dec 20223:00 pmRNSBlock listing Interim Review
1st Dec 20223:00 pmRNSTotal Voting Rights
30th Nov 20227:05 amRNSAstraZeneca announces sale of West Chester site
29th Nov 20227:00 amRNSAstraZeneca to acquire Neogene Therapeutics
23rd Nov 20223:30 pmRNSDirector/PDMR Shareholding
14th Nov 20227:10 amRNSEnhertu recommended for EU approval in gastric
14th Nov 20227:05 amRNSImfinzi recommended for approval in the EU for BTC
14th Nov 20227:00 amRNSLynparza combo recommended in the EU for mCRPC
11th Nov 20227:00 amRNSImfinzi + Imjudo approved in US for lung cancer
10th Nov 20227:00 amRNSYTD and Q3 2022 Results
9th Nov 20227:00 amRNSFDA Advisory Committee recommends PT027 in asthma
4th Nov 20227:00 amRNSBeyfortus (nirsevimab) approved in EU
1st Nov 20223:00 pmRNSTotal Voting Rights
26th Oct 20227:00 amRNSCapivasertib Phase III trial met primary endpoints
25th Oct 20227:00 amRNSUpdate on MESSINA Phase III trial
24th Oct 20227:00 amRNSImfinzi + Imjudo approved in advanced liver cancer
3rd Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202210:30 amRNSBoard Committee Changes
27th Sep 20227:05 amRNSKoselugo approved in Japan for NF1
27th Sep 20227:00 amRNSTezspire approved in Japan for severe asthma
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
22nd Sep 20227:00 amRNSLynparza approved in China for ovarian cancer
21st Sep 20227:00 amRNSTezspire approved in the EU for severe asthma
20th Sep 20227:00 amRNSEvusheld approved in EU for COVID-19 treatment
16th Sep 20227:10 amRNSDanicopan Phase III trial met primary endpoint
16th Sep 20227:05 amRNSEvusheld positive CHMP opinion in EU
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.